PortfoliosLab logoPortfoliosLab logo
Adicet Bio, Inc. (ACET)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US0070021086
CUSIP
007002108
IPO Date
Jan 26, 2018

Highlights

Market Cap
$46.93M
Enterprise Value
$25.94M
EPS (TTM)
-$19.17
EBITDA (TTM)
-$122.11M
Year Range
$6.01 - $17.44
Target Price
$18.00
ROA (TTM)
-60.72%
ROE (TTM)
-73.36%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Adicet Bio, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Adicet Bio, Inc. (ACET) has returned -19.12% so far this year and -43.63% over the past 12 months.


Adicet Bio, Inc.

1D
11.46%
1M
-6.07%
YTD
-19.12%
6M
-47.47%
1Y
-43.63%
3Y*
-58.04%
5Y*
-49.62%
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jan 26, 2018, ACET's average daily return is -0.06%, while the average monthly return is -1.84%.

Historically, 41% of months were positive and 59% were negative. The best month was Jul 2018 with a return of +68.2%, while the worst month was Nov 2019 at -83.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.

On a daily basis, ACET closed higher 47% of trading days. The best single day was Jul 25, 2018 with a return of +49.5%, while the worst single day was Nov 15, 2019 at -86.3%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-5.11%-9.26%-6.07%-19.12%
2025-8.00%1.56%-16.00%-12.30%8.49%-15.08%12.39%5.02%12.53%-7.43%-13.57%-18.81%-45.30%
202458.20%-21.40%0.00%-36.60%-2.68%-16.55%24.79%-3.31%-1.37%-11.11%-11.72%-14.87%-49.10%
20232.35%-13.88%-26.90%1.39%-6.16%-55.66%9.88%-25.09%-31.50%-3.65%-10.61%60.17%-78.86%
2022-27.84%3.65%52.68%-26.19%-19.81%23.52%15.68%-16.16%0.42%15.96%10.25%-50.83%-48.89%
2021-12.46%24.47%-14.57%21.79%-15.76%-23.32%-28.09%12.84%-6.11%9.69%23.72%64.38%24.48%

Benchmark Metrics

Adicet Bio, Inc. has an annualized alpha of -24.76%, beta of 1.13, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since January 29, 2018.

  • This stock participated in 214.23% of S&P 500 Index downside but only 5.75% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-24.76%
Beta
1.13
0.05
Upside Capture
5.75%
Downside Capture
214.23%

Return for Risk

Risk / Return Rank

ACET ranks 18 for risk / return — in the bottom 18% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


ACET Risk / Return Rank: 1818
Overall Rank
ACET Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
ACET Sortino Ratio Rank: 2323
Sortino Ratio Rank
ACET Omega Ratio Rank: 2323
Omega Ratio Rank
ACET Calmar Ratio Rank: 1313
Calmar Ratio Rank
ACET Martin Ratio Rank: 1212
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Adicet Bio, Inc. (ACET) and compare them to a chosen benchmark (S&P 500 Index).


ACETBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.48

0.90

-1.38

Sortino ratio

Return per unit of downside risk

-0.29

1.39

-1.68

Omega ratio

Gain probability vs. loss probability

0.97

1.21

-0.24

Calmar ratio

Return relative to maximum drawdown

-0.77

1.40

-2.17

Martin ratio

Return relative to average drawdown

-1.40

6.61

-8.01

Explore ACET risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Adicet Bio, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Adicet Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adicet Bio, Inc. was 99.74%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current Adicet Bio, Inc. drawdown is 99.71%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.74%Feb 26, 20182034Mar 30, 2026
-6.75%Jan 29, 20182Jan 30, 20183Feb 2, 20185
-5.63%Feb 5, 20182Feb 6, 20184Feb 12, 20186
-0.88%Feb 14, 20181Feb 14, 20182Feb 16, 20183
-0.2%Feb 22, 20181Feb 22, 20181Feb 23, 20182

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Adicet Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Adicet Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ACET in comparison with other companies in the Biotechnology industry. Currently, ACET has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items